As one of the most successful tumor-targeted aptamers18,19, a nucleolin aptamer (AS1411, NucA) in phase II trial (NCT00740441) for treating metastatic renal cell carcinoma has been confirmed with excellent tumor-targeting property and exceptional safety20. The gene discussed is NUCLEOLIN; the disease is neoplasm.